All news

Charles River raises 2026 guide to at least 1.5% organic growth after Q3 EPS rises 27%

BioSpace · · AI-summarised by FinFlash

Charles River Laboratories posted third-quarter revenue of $982.7 million, down 2.2% as reported but up 4.7% organically. Non-GAAP earnings climbed 27.2% to $3.09 a share, with operating margin widening 330 basis points to 23.0%. Discovery and safety assessment sales were $596.3 million. The company lifted its 2026 organic growth outlook to at least 1.5% from 0-1% and set non-GAAP EPS at

So What?

Positive read for contract research demand and biotech-linked spending. Watch whether peers such as IQVIA and Labcorp see similar stabilisation.

Read original source

CRL company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.